TABLE 1

Overview of anti-GM-CSF drugs, mechanisms, and studies

Mechanism of actionDrugStudy populationPhase
Humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF)TJ003234Healthy individuals1
COVID-191b/2
GimsilumabAnkylosing spondylitis1
COVID-192
LenzilumabChronic myelomonocytic leukemia1
Relapsed or refractory large B-cell lymphoma1/2
COVID-193
OtilimabRheumatoid arthritis2b
Inflammatory arthritis2
COVID-192
NamilumabRheumatoid arthritis2
Chronic plaque psoriasis2
Spondyloarthritis2
Humanized IgG4 monoclonal antibody targeting GM-CSF receptor alphaMavrilimumabRheumatoid arthritis2b
Giant cell arthritis2
COVID-192
Betac-receptor-specific, fully human IgG4 monoclonal antibody (inhibitor of IL-3-, GM-CSF-, and IL-5-mediated functions)CSL311Asthma1